Clinical Trial

Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls

Study acronym: OxyMOTION
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to investigate the potential beneficial effects of intranasal oxytocin compared to placebo on emotion recognition and acute psychosocial stress in patients with arginine vasopressin deficiency compared to matched healthy controls.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-04; most recent amendment 2025-05-22.
Status change: Not Yet Recruiting → Recruiting 2025-05-22
Trial Details
NCT Number NCT06676774
Lead Sponsor University Hospital, Basel, Switzerland
Conditions Arginine Vasopressin Deficiency, Diabetes Insipidus
Enrollment 42 participants
Start Date 2025-05-16
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-05-23